Article

New Agent Significantly Improves Progression-Free Survival in Patients With Advanced ER+ Breast Cancer

Author(s):

Bonnie Gillis

Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.

Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.

Click here to view this article.

Related Videos
Marcelo Kugelmas, MD | Credit: South Denver Gastroenterology
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Related Content
US FDA logo in black over a white background. | Credit: US Food and Drug Administration
November 23rd 2024

FDA Approves Acoramidis (Attruby) for ATTR-CM

Patrick Campbell
Medical Ethics Unpacked: Ethical Considerations for Euthanasia and Medically-Assisted Suicide
November 22nd 2024

Medical Ethics Unpacked: Ethical Considerations for Euthanasia & Medical Assistance in Dying

Steven Levine, MD Dominic Sisti, PhD
Gildeuretinol for Stargardt Secures FDA Rare Pediatric, Fast Track Status | Image Credit: Vitreo Retinal Associates
November 22nd 2024

Gildeuretinol for Stargardt Secures FDA Rare Pediatric, Fast Track Status

Connor Iapoce
Medical Ethics Unpacked:
November 22nd 2024

Medical Ethics Unpacked: Ethical Foundations and Background of Euthanasia & Medically-Assisted Suicide

Steven Levine, MD Dominic Sisti, PhD
Study Identifies Homelessness as a Predictor Against Clozapine Use
November 22nd 2024

Study Identifies Homelessness as a Predictor Against Clozapine Use

Chelsie Derman
FDA Issues CRL to Avacincaptad Pegol sNDA for Geographic Atrophy | Image Credit: US Food and Drug Administration
November 22nd 2024

FDA Issues CRL to Avacincaptad Pegol sNDA for Geographic Atrophy

Connor Iapoce
© 2024 MJH Life Sciences

All rights reserved.